X

Trial Profile

A Phase II trial of BXQ-350 in patients with Glioblastoma Multiforme (GBM)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Saposin C (Primary)
Indications Glioblastoma; Glioma; Solid tumours
Focus Therapeutic Use
Sponsors Bexion Pharmaceuticals

Most Recent Events

29 Sep 2021 According to a Bexion Pharmaceuticals, the company plans to initiate two adult Phase 2 programs in 2021-2022.
22 Feb 2021 According to a Bexion Pharmaceuticals, the company plans to initiate two adult Phase 2 programs in 2021.
30 Apr 2019 According to a Bexion Pharmaceuticals, proceeds from increase in series B funding will support this trial as well as two other studies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com